Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

Allogeneic hematopoietic cell transplantation (HCT) is a curative treatment for many hematologic malignancies and nonmalignant disorders. Chronic graft-versus-host disease (GVHD) is a leading cause of late morbidity and mortality in transplant survivors, compromising both quality of life (QOL) and function [1]. Ocular involvement is common in patients with chronic GVHD, occurring in more than fifty percent [2-5]. Since the ocular surface can be evaluated by physicians and ophthalmologists, it is important for all health professionals taking care of HCT recipients to have adequate knowledge of ocular GVHD.

Source: Biology of Blood and Marrow Transplantation - November 24, 2018 Category: Hematology Authors: Yoshihiro Inamoto, Nuria Vald és-Sanz, Yoko Ogawa, Monica Alves, Luigi Berchicci, John Galvin, Hildegard Greinix, Gregory A. Hale, Biljana Horn, Debra Kelly, Hien Liu, Scott Rowley, Helene Schoemans, Ami Shah, Maria Teresa Lupo Stanghellini, Vaibhav Agra Source Type: research